Standout Papers
- Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer (2013)
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer (2011)
Immediate Impact
2 by Nobel laureates 9 from Science/Nature 78 standout
Citing Papers
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
2024 Standout
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
Works of S. Phan being referenced
Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)
2019
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
2011 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| S. Phan | 1604 | 1340 | 489 | 531 | 43 | 2.4k | |
| Amrita Desai | 1292 | 1088 | 649 | 255 | 35 | 2.3k | |
| Holger Thurm | 1380 | 1623 | 604 | 236 | 46 | 2.1k | |
| James A. Reeves | 1637 | 1386 | 908 | 270 | 58 | 2.5k | |
| Susan C. Guba | 1288 | 764 | 658 | 228 | 49 | 2.3k | |
| Christian Scheffold | 1022 | 991 | 865 | 276 | 74 | 2.2k | |
| Maya Gutierrez | 1900 | 907 | 994 | 309 | 30 | 2.9k | |
| Peter N. Morcos | 2342 | 2787 | 870 | 284 | 48 | 3.5k | |
| Garry Schwartz | 1046 | 716 | 750 | 327 | 40 | 2.0k | |
| Cristian Massacesi | 1612 | 1052 | 970 | 242 | 64 | 2.3k | |
| Dana T. Aftab | 869 | 567 | 794 | 178 | 45 | 1.8k |
All Works
Loading papers...